10161075Assess Commercial Potential for Early HVD Screening with LightScopeActiveFeasibility StudiesInnovate UKHeart Valve Disease (HVD) affects 1.5 million---roughly one in four adults over 65 (1). Women are 50% more likely than men to be misdiagnosed and twice as likely to die as a result, while ethnic minorities and those in deprived areas face even higher barriers to early detection (2) . Late diagnosis also drives preventable hospital admissions, doubles treatment costs, and undermines quality of life. Our data show that 80% of GP-initiated valve-disease referrals turn out to be false positives---each one triggering needless echocardiograms, wasted clinical time, and extra carbon emissions at odds with the NHS's Net Zero goals. Recognizing this urgent need for earlier, more accurate HVD detection, we have developed a radically different approach. LightScope is our contactless, laser-based device that captures high-fidelity heart-sound and flow-dynamic data, ECG waveforms, and respiratory signals in under 15 seconds---no stethoscopes, cuffs, patient undressing, or specialist operators required. Our first CE-ready AI model already detects moderate-to-severe valve lesions (e.g., aortic stenosis, mitral regurgitation) with \>99% accuracy. But a breakthrough device alone isn't enough---we must understand how to embed it into real clinical pathways. In interviews with GPs, community pharmacists, ICB commissioners, cardiologists, and Heart Valve Voice (a valve disease charity), stakeholders unanimously confirmed the scale and human cost of under- and misdiagnosed HVD---especially among women and underserved groups---yet admitted uncertainty over which NHS or private budgets could support this tool. This £100 k feasibility project will therefore: 1. Map willingness-to-pay and commissioning models across primary care, pharmacies, and specialist clinics. 2. Co-design integration workflows that minimize clinician burden and maximize patient access. 3. Conduct rapid PPIE usability testing with target cohorts to ensure inclusivity. Deliverables include a prioritized customer map, detailed pathway blueprints, and a patient acceptability report. By pinpointing who will pay---and how---we'll de-risk our go-to-market strategy and enable LightScope to transform HVD screening, closing the diagnosis gap and improving outcomes across the NHS.